Cosciens misses primary endpoint in Phase 3 trial

 Top-line data with unexpected results requiring further clarification, did not meet primary endpoint as per protocol

- Potent growth hormone release following macimorelin stimulation

- Safety of macimorelin confirmed in the pediatric population

While we expect the top-line data of our DETECT-trial to be further analyzed and discussed with health authorities, macimorelin is approved in the USA and continues to be marketed in Europe for AGHD. As we get the results of further analysis of the DETECT-trial we will be considering our action plan for macimorelin. In addition, we will continue our ongoing review and prioritization process for COSCIENS’ pipeline. 

https://www.globenewswire.com/news-release/2024/08/27/2936131/0/en/COSCIENS-Biopharma-Inc-Announces-Top-Line-Results-of-Phase-3-DETECT-Trial-for-the-Diagnosis-of-Childhood-Onset-Growth-Hormone-Deficiency.html